GMM Pfaudler appoints Ankit Nayyar as Group CFO from Nov 4
- Ankit Nayyar appointed Group CFO effective November 4, 2026
- Alexander Poempner resigns to pursue new opportunities
- Poempner remains with firm until December 31, 2026 for handover
- Nayyar joins as Deputy CFO in May 2026 before promotion
- Board approved changes in September 15, 2026 meeting

*this image is generated using AI for illustrative purposes only.
GMM Pfaudler has appointed Ankit Nayyar as Group Chief Financial Officer, effective November 4, 2026, succeeding Alexander Poempner who is resigning to pursue new opportunities.
Leadership transition details
The Board of Directors approved the change in its meeting held on September 15, 2026. Mr. Poempner will cease to be Group CFO and Key Managerial Personnel (KMP) following the conclusion of the Board Meeting that approves the unaudited financial results for Q2 FY27.
Mr. Poempner will continue with the organization until December 31, 2026, to ensure an orderly handover and provide transition support. The Board expressed appreciation for his leadership and contributions over the last five years.
| Parameter | Details |
|---|---|
| Outgoing CFO | Alexander Poempner |
| Incoming CFO | Ankit Nayyar |
| Effective date of transition | November 4, 2026 |
| Handover completion date | December 31, 2026 |
| Reason for departure | To pursue new opportunities |
Mr. Nayyar joined the company as Deputy CFO in May 2026. He brings nearly two decades of experience across pharmaceuticals, specialty chemicals, manufacturing, and financial services. His recent roles include CFO at PI Health Sciences and leadership positions at Bayer, Monsanto India, Pfizer, MSCI, and Tata AIG Life Insurance. He is a Chartered Accountant with a Masters' in Accounting & Finance from Manchester Business School (UK) and a B.Com from Shri Ram College of Commerce.
Historical Stock Returns for GMM Pfaudler
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.07% | +17.43% | +34.29% | +55.00% | +17.44% | 0.0% |
How might Ankit Nayyar's background in pharmaceuticals and specialty chemicals influence GMM Pfaudler's strategic financial planning for its core manufacturing segments?
What potential impact could this CFO transition have on GMM Pfaudler's upcoming Q2 FY27 unaudited financial results and investor confidence?
Given Nayyar's experience with global firms like Bayer and Pfizer, will GMM Pfaudler likely pursue more aggressive international expansion or M&A activities under his leadership?

































